# Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)

> **NCT00478465** · PHASE1,PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 30 (actual)

## Conditions studied

- Chronic Fatigue Syndrome

## Interventions

- **DRUG:** valganciclovir

## Key facts

- **NCT ID:** NCT00478465
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00478465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00478465, "Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00478465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*